U.S. FDA Staff Reviewers Say Amgen's Late-Stage Trial May Not Provide Substantial Evidence To Support Claims Of Effectiveness For Co's Lung Cancer Drug
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA staff reviewers have expressed doubts about the effectiveness of Amgen's lung cancer drug, based on the company's late-stage trial results. This could potentially impact the approval of the drug.
October 03, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
FDA staff reviewers' doubts about the effectiveness of Amgen's lung cancer drug could potentially impact the approval of the drug and subsequently, the company's stock price.
The FDA's doubts about the effectiveness of Amgen's lung cancer drug, based on the company's late-stage trial results, could potentially delay or prevent the approval of the drug. This could negatively impact Amgen's revenues and subsequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100